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Abstract
Background
High shear force critically regulates platelet adhesion and thrombus formation during ischemic
vascular events. To identify genetic factors that influence platelet thrombus formation under
high shear stress, we performed a genome-wide association study (GWAS) and confirmatory
experiments in human and animal platelets.
Methods and Results
Closure times in the shear-dependent Platelet Function Analyzer (PFA)-100® were measured
on healthy, non-diabetic European Americans (n=125) and African Americans (n=116). A
GWAS significant association (p<5X10-8) was identified with 2 SNPs within the SVIL gene (chr
10p11.23) in African-Americans but not European Americans. Microarray analyses of human
platelet RNA demonstrated the presence of SVIL isoform 1 (supervillin) but not muscle-specific
isoforms 2 and 3 (archvillin, SmAV). SVIL mRNA levels were associated with SVIL genotypes
(p≤0.02) and were inversely correlated with PFA-100 closure times (p<0.04) and platelet volume
(p<0.02). Leukocyte-depleted platelets contained abundant levels of the ~205 kD supervillin
polypeptide. To assess functionality, mice lacking platelet supervillin were generated and backcrossed onto a C57BL/6 background. Compared to controls, murine platelets lacking supervillin
were larger by flow cytometry and confocal microscopy, and exhibited enhanced platelet
thrombus formation under high shear, but not low shear, conditions.
Conclusions
We show for the first time that 1) platelets contain supervillin, 2) platelet thrombus formation in
the PFA-100® is associated with human SVIL variants and low SVIL expression, and 3) murine
platelets lacking supervillin exhibit enhanced platelet thrombus formation at high shear stress.
These data are consistent with an inhibitory role for supervillin in platelet adhesion and arterial
thrombosis.
Key Words: platelets, genetics, thrombosis
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Introduction

Arterial thrombosis is a major cause of myocardial infarction (MI) and stroke. Most clinical
events occur when an atherosclerotic plaque ruptures to expose subendothelial collagen and
von Willebrand factor (VWF). These proteins bind to platelets triggering primary activation and
granule secretion.1 Secretion of soluble agonists, including ADP, amplifies activation and leads
to integrin activation, platelet-platelet aggregation and occlusive thrombus formation. Platelets
play a more prominent role in arterial thrombus formation than in venous thrombosis because
the highly specialized initial platelet-VWF interaction is enhanced by shear stress, such as
occurs in coronary arteries.2, 3
Platelet reactivity varies greatly among individuals. This variation exhibits strong
heritability in both European Americans (EA) and African Americans (AA)4, which could explain
some of the known genetic contribution to the risk of acute MI.5 Although genetic epidemiology
screens have identified loci associated with MI risk6, our understanding of causative genes is
limited. The use of intermediate phenotypes to identify genes involved in the pathophysiology of
arterial thrombosis can yield stronger genetic associations.7 Genome-wide association studies
(GWAS) have led to the discovery of key molecules regulating human disease8 and have
identified genetic variants and novel genes associated with platelet number, platelet volume and
in vitro platelet aggregation.9, 10 However, no GWAS has identified genes associated with shear
stress-dependent platelet function. The Platelet Function Analyzer-100® (PFA-100) measures
the time to platelet thrombus formation under a defined shear stress of 1500 sec-1 in whole
blood.11 The assay requires platelet tethering to VWF, firm adhesion to collagen, platelet
activation and secretion, and platelet aggregation mediated by VWF and fibrinogen. Abnormal
assay results correlate with platelet hyperfunction and hypofunction associated with acute
coronary syndromes12-15 and bleeding disorders, respectively.16, 17 The aim of this study was to
identify genetic factors that influence platelet reactivity and thrombus formation under high shear
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stress. We carried out a genome-wide screen with the PFA-100® to identify novel gene
variants in AAs and EAs. We identified a novel platelet gene, SVIL (encoding the cytoskeletal
regulatory protein, supervillin), whose expression negatively regulates platelet reactivity and
thrombus formation in both humans and mice.
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Methods
Subjects and platelet phenotyping. The Platelet Genes and Physiology study was
approved by the Institutional Review Boards of Baylor College of Medicine and Thomas
Jefferson University, and informed consent was obtained from all volunteers. Healthy donors
were recruited between 2000-2006 in Houston, Texas. Citrated whole blood was used to
measure PFA-100® closure times in a collagen and ADP-impregnated cartridge (hereafter
referred to as PFA-100ColA) within 30 min of phlebotomy. A platelet aggregation response of
<10% was considered as exposure to anti-platelet agents and reason for exclusion.
Genotyping. Genomic DNA was extracted from leukocyte buffy coats with the Qiagen
DNA extraction kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions.
DNA from AAs was genotyped on the Illumina Hum1M Beadarray. EA DNAs were genotyped
on the Illumina Hum550k Beadarray. Due to the lower levels of linkage disequilibrium (LD) in
African populations a denser SNP micorarray was selected to genotype the DNA samples from
AA individuals to improve tagging of causal variants.
Statistical analysis. Quality control was performed before statistical analysis. Subjects
were excluded for relatedness to other participants and for failing stringent genotyping quality
control. Individual genotypes that failed quality control were also removed (see Supplemental
Methods for details). PFA-100ColA closure times were natural log transformed and tested for
associations using an additive model within a linear regression framework. All analyses of EA
and AA samples were performed separately. The potential confounders, age, sex, VWF
activity, plasma fibrinogen level and platelet CD41 level were tested for significance using
forward selection and significant covariates were retained within the model (p-value < 0.1).
Principal Components Analysis (PCA) was also performed on the data using a subset of the
SNP markers that are in linkage equilibrium (r2<0.3).18 To evaluate if there is inflation of the test
statistic due to population substructure/admixture, lambda, was estimated when both no PCA
components and when one through five PCA components were included in the linear regression
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model. For those SNPs that met GWAS significance (p-value < 5 X10-8) a dominance
parameter was tested in a linear regression model in order to determine whether the data fit an
additive model where the genetic effect for the heterozygous genotype is between that of the
genetic effects for the two homozygous genotypes for the major, reference allele, and the minor
allele.
Platelet gene expression analysis. RNA from leukocyte-depleted platelets (LDP) was
prepared for gene expression profiling in 29 healthy subjects. LDP was prepared using density
centrifugation followed by CD45-positive cell depletion of platelet rich plasma (PRP).19 As
controls, RNA from PRP and from the CD45+ leukocyte fraction was extracted from 11 and 5
subjects, respectively, using TRIzol® (Invitrogen, Carlsbad, CA). Gene expression analysis was
performed using the Sentrix BeadChip and BeadStation system from Illumina, Inc. (San Diego,
CA).20
Platelet supervillin expression and correlation with PFA-100ColA. LDP RNA was used
to validate the SVIL microarray data.19 Total LDP RNA was reverse transcribed and PCRamplified using a sense primer in exon 1 and an antisense primer in exon 5. Immunoblotting of
6% SDS-PAGE gels was performed with 4 different anti-supervillin antibodies to verify platelet
expression. Natural log transformed mRNA expression data from microarrays was plotted vs.
PFA-100ColA closure times for the 23 individuals for whom both values were available.
Pearson correlation r- and P-values were calculated using GraphPad Prism software (La Jolla,
CA).
Mouse platelet phenotyping. Mice lacking Svil were generated and back-crossed ten
times onto a C57BL/6 background. Svil-/- and control C57BL/6 mice were maintained by
homozygous breeding. Platelet thrombus formation under shear stress was measured using
microfluidic flow chambers with immobilized collagen.21 Blood from 3 wild type and 3 Svil -/mice was studied. Experiments were performed over 4 different days, with 3-4 runs per day (a
“run” defined as data acquisition from platelet deposition in a single flow chamber) for a total of
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15 runs per wild type and 15 runs per Svil -/- genotypes. P values were computed using a twoway repeated measures, linear mixed effects ANOVA model that accounts for the main effect of
genotype with GraphPad Prism.
Flow Cytometry. Whole blood was diluted into Tyrode’s buffer containing 1 mM CaCl2,
and stained with FITC-α-CD41 (BD Pharmingen) or PE-α-GPIbα (Emfret Analytics, Würzburg,
Germany). After dilution with PBS the cells were analyzed on a FACScan.
Immunofluorescence confocal microscopy. Platelets adhered to glass slides statically,
or to collagen coated coverslips statically or under high shear were stained with Alexa-568
phalloidin and α-myosin IIA antibodies and imaged using confocal microscopy.
Additional details are available in the Supplemental Methods.
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Results
SNPs within SVIL are associated with platelet function under shear stress

To assess the capacity for platelet thrombus formation under shear stress, PFA-100ColA
was used to measure PFA-100® closure times in a cohort of healthy, non-diabetic subjects (the
Platelet Genes and Physiology [PGAP] study). For this genetic study, only subjects selfidentified as EA or AA were considered. Blood was collected for PFA-100ColA testing on 154
AAs and 157 EAs. The PFA-100ColA closure time data were normally distributed in both
groups (not shown). The DNA from each subject was genotyped for 620,901 or 1,070,000
tagSNPs for EAs or AAs, respectively, using the Infinium II platform. Exclusion criteria included
NSAID use, subject relatedness and failing genotyping quality control (described in the Methods
and in the Supplemental Materials). Table 1 summarizes the demographics of the 116 AA and
125 EA subjects who were analyzed.
The PFA-100ColA phenotype was tested for association with each genotype under an
additive model. Using log-transformed values of the PFA-100ColA phenotype, analysis was
performed using linear regression, controlling for sex, age, CD41 and VWF activity in AAs, and
sex and VWF activity in EAs. For AAs, age (p=~10-2), sex (p=~10-2), CD41 (p=~10-2) and VWF
activity (p=~10-9) were significant and were retained in the model. For EAs, only sex (p=~10-2)
and VWF activity (p=~10-9) were significant, so only these covariates were included in the
analysis. PCA components were not included in the analysis, because lambda=1.0 indicating no
inflation in the test statistic due to population substructure/admixture. Figure 1A shows
Manhattan plots for genotype associations with PFA-100ColA closure times, with a prominent
“peak” observed in chromosome 10 for AAs. Table 2 lists the SNPs with the 12 lowest P values
for AAs. Notably, 5 of these SNPs were clustered within ~21.8 kb of 4 exons within the SVIL
gene, which encodes differentially spliced isoforms of supervillin and archvillin. The most
significant SNP, rs7070678 (p=3.6 x 10-8), which is a synonymous SNP in exon 14 of the SVIL

CIRCULATIONAHA/2012/091462/R2-9
gene, is in LD with other SNPs within the SVIL gene but not with SNPs in neighboring genes
(Figure 1B). A second SNP, rs10826650, within the SVIL gene (intron 13) also reached GWAS
significance (p<5X10-8). Three additional SNPs (rs7910521, rs10826649, rs7913801) within
introns 16 and 17 of the SVIL gene had p-values in the order of 10-6. To determine whether or
not an additive model best fit the data for the SNPs within the SVIL gene, a dominance
parameter was included in the analysis. However, because the dominance parameter was not
significant, it was not included in the model. This parameter was not significant, indicating no
more explanatory power was derived from a dominant model. The closest other well-annotated
genes in this region, LYZL1 (lysozyme-like 1) and KIAA1462, were >214 kb from the SVIL SNPs
listed in Table 2, and there was no evidence of an association with either of these genes. The
clustering of SNPs with p values of ~10-8 suggested that genetic variants in SVIL (and not
another gene) are associated with PFA-100ColA closure times in AAs. No associations with
GWAS significance were detected with SNP marker loci within the SVIL gene within EA,
although 3 additional SVIL SNPs had weak associations in EA (p<10-2).

Supervillin mRNA and protein are present in human and mouse platelets

Figure 2 illustrates the SVIL exon structure, the two major known mRNAs and the
location of rs7070678, the SNP with the strongest association with PFA-100ColA closure times.
SVIL encodes supervillin, which has a broad cell distribution, and 2 archvillin isoforms, which
are enriched in muscle.22-24 Supervillin forms a high-affinity link between the actin cytoskeleton
and the plasma membrane22 but has not been described in platelets. Because integrin function
and rearrangements of the actin cytoskeleton are a crucial aspect of the platelet adhesive
process25, we therefore sought to characterize supervillin in platelets.
Platelet RNA expression analysis was performed with LDP RNA samples from 29
healthy subjects. Probes from the 5’-most and 3’-most exons (Figure 2A) were readily

CIRCULATIONAHA/2012/091462/R2-10
detectable. However, an RNA signal was not detected for probe ILMN_1659306, which is
specific for archvillin and SmAV. Platelet SVIL transcripts are expressed at moderately high
levels, and are higher than PECAM-1 but lower than GPIb mRNAs (supplemental Figure 1).
Supervillin transcripts were easily detected in LDP RNA by RT-PCR (Figure 2B), validating the
microarray data. Figure 2C shows SVIL mRNA levels for LDP, PRP and CD45+ leukocytes
(WBC) as box plots.
Western immunoblotting identified supervillin at ~205 kDa in PRP (Figure 3A). This
polypeptide migrated slightly faster than that seen in control A549 cells, so additional antisera
was used to confirm platelet supervillin Mr and immunoreactivity. The locations of the epitopes
recognized by these antibodies are shown in Figure 3B. In addition, because supervillin is
present in leukocytes,26, 27 we also analyzed LDP and leukocyte-enriched buffy coat. Using two
other antibodies, 205 kDa supervillin was again detected in platelets, as well as in the
megakaryocyte cell line, Meg-01, but was not detected in CD45-enriched leukocytes or K562
erythroleukemia cells (Figure 3C, 3D). Finally, supervillin was present in mouse platelets
(Figure 3E). Sequencing of platelet SVIL mRNA RT-PCR products revealed the same splice
form as is present in HeLa cells (not shown).

Supervillin mRNA levels correlate with platelet function under shear, platelet size and with the
rs7070678 genotype

Because platelet protein was available from only a few of the 29 subjects used in the
platelet RNA expression analysis, we used SVIL mRNA levels to test for a correlation with
platelet function. Figure 4A shows that SVIL mRNA levels correlate with PFA-100ColA closure
times (p = 0.038). Since longer closure times indicate reduced platelet function, these data
suggest SVIL expression may inhibit human platelet thrombus formation under shear stress. A
trend was observed for a similar relationship between SVIL mRNA expression and collagen-
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induced platelet aggregation (p = 0.07), but not with ADP-induced platelet aggregation (p =
0.23; data not shown). SVIL mRNA levels also correlated negatively with human mean platelet
volume (p = 0.016) (Figure 4B). Because both SVIL SNPs and SVIL transcripts were
associated with PFA-100ColA closure times (Figures 1 and 4), we tested whether SVIL SNPs
were associated with SVIL mRNA levels using a recessive model analysis. Figure 4C shows
that SVIL expression differed significantly by rs7070678 genotype.

Platelets from Svil deficient mice form thrombi faster under shear in flow chamber studies

To further address the role of supervillin in platelet function, we generated mice from
BayGenomics ES cells bearing an insertion in the supervillin (Svil) gene (Figure 5). In this
mouse, a -galactosidase/neomycin phosphotransferase (-gal/neo) gene trap inserted into the
large intron downstream of the 13th of the 34 coding exons (Figure 5A) disrupts expression of
all characterized Svil splice-forms (not shown).22-24 The location of the insertion was verified by
Southern blotting, which showed that a Bgl II restriction site from the pGT0lxf vector reduced the
11.5-kb Bgl II fragment including coding exon 13 to 7.2 kb (not shown), and by PCR (Figure 5B)
with primers specific for either the wild-type (WT) or mutated (Mut) locus (Figure 5A, arrows).
This insertion destabilizes the message or protein because supervillin is effectively absent from
murine Svil -/- platelets (Figure 5C) and leukocytes (not shown).
To assess the role of supervillin in platelet thrombus formation under shear stress, we
analyzed wild-type and Svil-/- platelets in microfluidic flow chamber assays on immobilized
collagen.21 No difference was observed under the “venous” flow rate of 400 sec-1 (Figure 6A6B), but Svil -/- platelets showed greater deposition (P<0.05) under arterial flow rates of 1200
sec-1 (Figure 6C-E). Both percent coverage of the collagen-coated area, indicating platelet
adhesion to collagen, and sum intensity, indicating thrombus formation, were affected.
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Although there was no difference between wild-type and Svil-/- mice in platelet numbers,
Svil-/- platelets appeared to be larger as measured by both forward scatter in flow cytometry
and confocal microscopy (Table 3), consistent with the relationship in humans (Figure 4B).
However, these larger platelets did not express correspondingly greater levels of major surface
adhesion receptors, integrin IIb or glycoprotein Ib (Table 3).
Supervillin directly binds F-actin, myosin II heavy chain, filamin, and many other
cytoskeletal proteins.28-31 To better elucidate the cytoskeletal and structural differences between
wild-type and Svil-/- platelets, we analyzed F-actin and myosin IIA organization using
immunofluorescence confocal microscopy. Although these platelet cytoskeletons are similar in
appearance when statically adhered to glass (Figure 7A-B vs 7C-D), Svil-/- platelets are more
highly spread after activation under high shear flow across collagen (Figure 7E-F vs 7G-H). The
intensity of F-actin staining increases after activation of both types of platelets, as expected
given the associated polymerization of actin.32, 33
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Discussion
Inter-individual variation in platelet reactivity contributes to common arterial thrombotic
disorders in humans, but there is only a limited understanding of the responsible molecular
mechanisms. We screened a cohort of healthy human subjects by genome-wide genotyping for
associations with platelet function assessed under shear stress, and identified a candidate gene
in AA that was validated using gene expression and platelet physiology approaches. Our major
findings were that 1) genetic variants in SVIL were associated with closure times in the PFA100ColA, 2) platelets contain supervillin and little or no archvillin or SmAV, and 3) low or absent
platelet supervillin is associated with enhanced thrombus formation under high shear and
increased platelet size in both humans and mice.
Growing evidence supports a role for supervillin as a regulator of cytoskeletal-membrane
interactions. Among other functions, supervillin increases myosin II contractility, reduces
integrin-mediated cell adhesion, and promotes rapid integrin recycling.34-36 Our data support an
inhibitory role for supervillin in regulating the rapid activation and spreading of platelets during
thrombus formation on collagen under shear stress, an important determinant of platelet
responsiveness in arterial thrombosis. These results are consistent with supervillin inhibition of
spreading and integrin function in other cell types.44-45
Genome wide associations study. The PFA-100® is dependent upon shear stress and
is relatively “high-throughput.” We appreciate that some12-15, but not all37, 38, clinical
cardiovascular outcome studies have observed associations with PFA-100 results. The lack of
an association between PFA-100 results and clinical outcomes may be due to some nonphysiological conditions, such as anticoagulated blood or an absence of vessel wall. It would be
ideal to replicate our findings with other assays in humans, however neither light transmission
aggregometry nor impedance aggregometry are performed under conditions considered to
apply shear stress to platelets. Our strategy was to use the GWAS as a screen for identifying
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novel genes associated with shear-dependent platelet reactivity. However, our study differs
from prior platelet genomics studies in that our validation approach employed mRNA expression
and physiology experiments. Our statistical analysis was strengthened by the ability to adjust
for confounders known to affect platelet adhesion (VWF activity) and aggregation (CD41 levels),
which were also shown to be significant in the analysis. Two SNPs in SVIL met the threshold
for genome-wide significance in AA, and 3 additional SVIL SNPs associated with PFA-100ColA
closure times with p values of 10-6.
The reason for our inability to detect a similarly strong association in EA is unclear, but
probably relates to limited power of a small sample size by typical GWAS standards and the fact
that minor allele frequencies were ~20% lower in EAs. Thus, much larger sample sizes might
be necessary to detect an association in EAs. Indeed, supplemental data in the genomic
analysis by Johnson et al. show modest associations (~10-5) between SNPs in SVIL and in vitro
platelet aggregation in both AAs and EAs 9.
None of the 5 SVIL SNPs associated with PFA-100ColA closure times were predicted to
affect the protein coding sequence, so we had no reason to suspect that any of these SNPs
directly altered supervillin function. This is not unusual since GWAS uses indirect association
mapping with tagSNPs that are in LD with causal variants8. However, despite a small sample
size comprised of both EA and AA in our RNA expression study, eQTL analysis supported an
association between these SNPs and SVIL mRNA levels (Figure 4C). Thus, at least one
genetic mechanism by which SVIL variants may regulate platelet reactivity is by altering SVIL
expression, perhaps via effects on transcription or mRNA stability.
SVIL expression in platelets. SVIL mRNA was detected in platelets using a 3’UTR probe
that recognizes all SVIL transcripts and a 5’UTR probe specific for nonmuscle supervillin (Figure
2). Archvillin mRNAs were not detected in our microarray expression study, consistent with
prior data indicating that archvillin and SmAV are mainly expressed in muscle 23. In addition to
the RNA data, immunoblotting with multiple antibodies demonstrated the presence of abundant
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supervillin protein in platelets. Using microarray analysis, Watkins et al. reported that SVIL
mRNA is expressed in multiple hematopoietic cell types including CD4+ and CD8+ T-cells,
CD14+ monocytes , CD19+ B-cells, CD56+ natural killer cells, and CD66b+ granulocytes 27. We
also observed SVIL mRNA in CD45+ cells (Figure 2C), found supervillin protein in murine
thymocytes, splenocytes, macrophages, and neutrophils by immunoblotting (unpublished data),
and recovered Coomassie blue-staining amounts of supervillin from bovine neutrophils 26.
While high levels of proteases may have caused degradation in human leukocyte lysates
(Figure 3), supervillin is clearly expressed at moderately high levels in platelets (Figures 2C and
3, Suppl. Fig. 1). And since PRP has some contamination with WBCs, our gene expression
data suggest that SVIL mRNA is expressed at higher levels in platelets than WBCs (Fig. 2C).
The basis for the reproducibly faster migration of platelet supervillin, as compared with HeLa
and A549 cell supervillin (Figure 3), is unclear because the predicted mRNAs are identical. A
likely explanation is a cell type-specific difference in post-translational modifications.
Supervillin and platelet size. Supervillin expression levels are inversely correlated with
platelet size in both humans and mice. Although Svil-/- platelets are larger, they do not have
greater surface expression of several critical adhesive glycoproteins (GPIb or integrin IIb),
suggesting a possible membrane cytoskeletal defect, rather than premature release of larger
platelets from megakaryocytes. There are several possible mechanisms by which supervillin
might regulate platelet size. Filamin anchors the GPIb-IX-V complex to the platelet cytoskeleton
and binds to supervillin 31, 39; an altered filamin-GPIb interaction could produce larger platelets,
such as those characteristic of inherited mutations in the gene encoding GPIb 40, 41. Other
possible mechanisms include altered myosin II function similar to the MYH9-associated
macrothrombocytopenias 42, or a simple disruption of the actin cytoskeleton that maintains
normal platelet size, as in the Wiskott-Aldrich syndrome 43. The increased platelet size may
enhance thrombus formation since high platelet volumes have been associated with MI
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Supervillin and platelet function. Supervillin effects on platelet function are most
prominent under shear stress. Healthy human subjects expressing higher levels of SVIL mRNA
exhibit slower platelet thrombus formation in the PFA-100ColA. Platelets in blood from
supervillin-deficient mice form thrombi faster under high shear rates in flow chamber studies
than is observed for platelets with wild-type Svil (Figure 6). Although the effect of supervillin on
platelet adhesion is not dramatic, it is difficult to demonstrate gain-of-function effects, and the
increased adhesion observed in Svil null platelets is well in line with other mouse mutants of
signaling molecules that limit platelet activation.44, 45 The mice used in these studies have Svil
defects in all tissues, and we cannot exclude an indirect effect on platelets. However, the SVIL
association studies used here and by Johnson et al. 9 utilized an in vitro platelet assay
consisting only of platelets and plasma (i.e., aggregometry). Taken together, our results
strongly suggest an inhibitory role for supervillin in platelet function. .
An inhibitory effect during spreading is consistent with the larger surface profiles
observed for supervillin-deficient platelets on collagen after 2 min of flow under high shear
(Figure 7). The direction of this effect is consistent with a number of mechanisms. First, the
larger initial volumes of unactivated Svil-/- platelets (Table 3) may contribute to their larger
surface areas after activation. Second, the loss of supervillin could increase the rate of cell
spreading by increasing integrin adhesion to the substrate, or by decreasing myosin II-mediated
slowing of the cell spreading rate, as observed in other cell types 34, 35. Finally, decreased
integrity of the membrane-cytoskeleton connection could increase the apparent cross-sectional
surface area if Svil-/- platelets are more sensitive to cortical disruption by high shear forces.
Further studies are needed to determine which supervillin interactions regulate the early phases
of platelet activation and adhesion under high-shear forces.
There are potential clinical implications to our findings. If confirmed in additional studies,
these data suggest that SVIL variants may contribute to predisposition to cardiovascular
disease in AA. Targeting supervillin in a manner that would enhance its activity might have anti-
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thrombotic benefit for arterial vascular disease like MI and stroke, a benefit that may be more
pronounced in African Americans. Conversely, drugs that interrupt supervillin function in
platelets could have untoward effects of promoting thrombosis. Lastly, SNPs in strong LD with
the causative SVIL variant may be useful as a biomarker for risk of thrombosis or hemorrhage.
Summary. Combined genome-wide technologies in a cohort with well-characterized
platelet function have led to the identification of a novel protein in platelet biology. We have
identified a candidate gene meeting GWAS significance, and both human and mouse studies
support an inhibitory effect of supervillin in platelet thrombus formation under shear stress.
Although the causative variant in SVIL has not been identified, these data indicate that genetic
variations in SVIL expression contribute to variations in human platelet reactivity and support a
role for supervillin in arterial thrombosis. Further analysis of SVIL variants may lead to a better
understanding of the genetic basis for susceptibility to arterial thrombosis.
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Figure Legends

Figure 1
GWAS with PFA-100ColA. (A) Manhattan Plots for PFA-100ColA. The Manhattan plot is shown
for all autosomes for European and African Americans. The y-axis shows the –log10 of the pvalues for the chromosomes numbered on the x-axis. For the African Americans the two most
significant SNPs are rs7070678 and rs10826650 in SVIL; both meet genome-wide significance
with p-values of 3.6x10-8 and 4.4x10-8, respectively. None of the SNPs within SVIL meet
genome-wide significance for European Americans. (B) SVIL region association plot on
chromosome 10 for African Americans. The most significant SNP rs7070678 is displayed, and
the amount of linkage disequilibrium between this SNP and nearby SNPs is shown as a heat
plot with SNPs in strongest LD with rs7070678 in darker colors. The significance level is
displayed on the y-axis as –log 10 of the p-values. The rate of recombination within the region
is shown as the light blue tracing. The regions containing the SVIL and LYZL1 genes are
indicated by green arrows.

Figure 2
SVIL genomic region and transcript expression. (A) Exon structure of SVIL at
Chr10:29,786,283-29,963,907 with exons of the two major transcripts (NM_003174,
NM_021738) shown as lines and boxes. The location of the 1st of the 5 SNPs (rs7070678)
from Table 2 is shown by thin vertical arrows. The locations of the microarray probes are
indicated by the thick vertical arrows and ILMN ID numbers. Horizontal arrows indicate the
positions of the sense and antisense PCR primers. (B) Ethidium-stained agarose gel showing
RT-PCR products of leukocyte-depleted platelet (LDP) RNA and primers specific for ITGA2
(CD41, integrin IIb) and SVIL. Neg, no template control. (C) Box plot showing the levels of
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SVIL mRNA (ILMN_1671404) in LDP (n=29), PRP (n=11) and CD45+-leukocytes (WBC; n=5).
Box represents interquartile range and whiskers represent 5% - 95% range.

Figure 3
Platelet supervillin expression. (A) Immunoblot of PRP and, as a positive control, the A549
human alveolar adenocarcinoma cell line. Blots were probed with anti-supervillin (SVIL) and
anti-CD41 (platelet integrin IIb) antisera and imaged on a LI-COR Odyssey. GAPDH, loading
control. (B) Supervillin protein schematic showing locations of the gelsolin/villin homology
repeats, the binding sites for myosin II heavy chain (Myo II) and F-actin, and the epitopes for the
4 antibodies used (H340, Ab50856, HPA02013 and S8695). (C) Immunoblot probed with antiSVIL antibody S8695 and anti-CD45. The erythroleukemia K562 and megakaryocytic Meg-01
cell lines are included. (D) Immunoblot with additional anti-SVIL antibodies. (E) Immunoblot
with H340 using lysates from mouse platelets and from A549 and HeLa adenocarcinoma cells,
as controls.

Figure 4
Correlation of SVIL mRNA levels with human platelet function. Natural log transformed SVIL
mRNA levels (VSTs) from the gene expression profiling were correlated with (A) PFA-100ColA
closure times, (B) mean platelet volume (MPV) and (C) SVIL expression levels based on
rs7070678 genotype.

Figure 5
Disruption of the Svil gene and loss of Svil expression in platelets. (A) Diagram of the wild-type
(WT) and mutated (Mut) Svil loci (top 2 lines) with enlargements (bottom 2 lines) showing the
insertion site (*) of the pGT0lxf vector sequence within the intron between coding exons 13 (E13) and 14 (E-14). Also shown are the locations of PCR primer sets diagnostic for the wild-type
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and mutant loci (arrows), the 0.8-kb probe used for Southern analyses, and the Bgl II sites
(triangles) associated with endogenous genomic DNA and with the inserted -galactosidaseneomycin (-gal/neo) coding sequence. (B) PCR of genomic DNA from mouse tails using the
primer sets shown in Panel A. Primers specific for the insertion identify a ~2.5-kb product (Mut,
top) while primers specific for the wild-type allele generate a 0.8-kb product (WT, below). (C)
Immunoblot of mouse platelets with anti-supervillin antibody (H340) and anti-tubulin as a loading
control.

Figure 6
Enhanced adhesion and thrombus formation in platelets lacking supervillin. Whole blood from
wild type (WT, black line) or Svil-/- (SVIL, red line) mice was perfused over immobilized collagen
at venous (400 s-1) or arterial (1200 s-1) shear conditions. Platelets in whole blood were labeled
with AlexaFluor488-labeled antibodies to platelet GPIX before perfusion. (A, C) Surface area
covered by platelets at indicated time points presented as % of coated collagen ± SEM. (B, D)
Sum fluorescence intensity ± SEM measured at the indicated time points. Experiments shown
in panels A-D were conducted on 4 different days for a total of 15 runs for each genotype. (E)
Representative images were taken at the designated times during perfusion at arterial (1200 s-1)
shear rates. Scale bars shown in 1-min images apply to all time points.

Figure 7
Immunofluorescence micrographs of (A, B, E, F) wild-type or (C, D, G, H) supervillin-deficient
platelets fixed (A-D) statically onto glass or (E-H) after activation for 2 min on collagen under
high-shear (1200 s-1) flow. F-actin (red) was visualized with AlexaFluor568-phalloidin; myosin
IIA (green) was stained with antibody. Bars, 2.5 µm, 0.5 µm, and 12.5 µm, as indicated.
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Table 1. Demographics of subjects in this genetic study.

Parameters

African American European Americans

No. of Subjects

116

125

Females

69%

50%

Mean Age (yrs) ± SD

35.0 ± 9.4

35.0 ± 11.1

Mean BMI (kg/m2) ± SD

28.6 ± 5.3

25.5 ± 4.6

Smokers

16.4%

32%

Hypertension

8.6%

3.4%

Hematocrit (%) ± SD

36.1 ± 5.0

37.4 ± 4.4

Fibrinogen (mg/dL) ± SD

345 ± 99

300 ± 64

VWF activity (%) ± SD

88 ± 38

79.7 ± 35

406,060 ± 93,350

430,550 ± 111,600

PRP platelet count (per µL) ± SD
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Table 2. Most significant p-values detected in genotype data from African Americans
SNP ID

Chr:position

Genes

β

Std

MAF*

Type

P value

.327

Exon 14

3.581 x 10-8

Error
rs7070678

10:29812602

SVIL

synonymous
-0.006807

rs10826650

10:29814284

SVIL
-0.006856

rs11858159

15:24824188

PWRN1

rs3901472

15:24814582

PWRN1

rs7656730

4:40159617

N4BP2

rs7910521

10:29803661

SVIL

rs10826649

10:29792539

SVIL

rs17783459

18:42329076

SETBP1

rs9890514

17:46738883

none

0.005737
0.005773
0.025637
-0.006104
-0.006142
0.032067
0.012391

rs1507740

1:163075021

.340

Intron 13

4.426 x 10-8

.366

Intron 7

9.1879 x 10-7

.379

Intron 3

1.034 x 10-6

.675

3’ UTR

1.044 x 10-6

.326

Intron 16

1.830 x 10-6

.297

Intron 17

2.382 x 10-6

.042

Intron 3

3.343 x 10-6

.196

-

3.604 x 10-6

.157

-

4.640 x 10-6

0.001253
0.001169
0.001182
0.005250
0.001279
0.001301
0.006898
0.002675

none
0.013215

* Minor allele frequency

0.001235

0.002885
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Table 3. Platelet parameters in wild type and Svil -/- mice.
Parameter

wild type

Svil -/-

P value*

Platelet number/L†

1,083,000

969,000

0.67

19.4

23.2

<0.0001

4.7 ± 0.1 (N=159)

5.3 ± 0.1 (N=241)

0.0045

Forward scatter‡

Surface area (µm2)§
Integrin αIIb , MFI || fold change#

1.02

0.89 (n.s.)

GPIbα, MFI || fold change#

1.30

0.40 (n.s.)

* Calculated by Student’s T-Test
†

By Hemavet 850FS (Drew Scientific)

‡ By FACScan (Becton Dickinson)
§ Means ± s.e.m. by confocal microscopy of AlexaFluor568-phalloidin stained unactivated

|| MFI, mean fluorescence intensity ratio of mutant/wild type platelets
# Flow cytometric comparisons between mice are shown as fold-changes to normalize for dayto-day variation in platelets, antibody fluorescence, binding, and acquisition.
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